MX2022011651A - Composicion farmaceutica para tratamiento de diabetes. - Google Patents

Composicion farmaceutica para tratamiento de diabetes.

Info

Publication number
MX2022011651A
MX2022011651A MX2022011651A MX2022011651A MX2022011651A MX 2022011651 A MX2022011651 A MX 2022011651A MX 2022011651 A MX2022011651 A MX 2022011651A MX 2022011651 A MX2022011651 A MX 2022011651A MX 2022011651 A MX2022011651 A MX 2022011651A
Authority
MX
Mexico
Prior art keywords
treating diabetes
administration
dapansutrile
directed
subject
Prior art date
Application number
MX2022011651A
Other languages
English (en)
Inventor
Charles A Dinarello
Original Assignee
Olatec Therapeutics Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Olatec Therapeutics Llc filed Critical Olatec Therapeutics Llc
Publication of MX2022011651A publication Critical patent/MX2022011651A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/275—Nitriles; Isonitriles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics

Landscapes

  • Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Diabetes (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Cardiology (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Endocrinology (AREA)
  • Emergency Medicine (AREA)
  • Hospice & Palliative Care (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Steroid Compounds (AREA)

Abstract

La presente invención está dirigida a una composición y método para tratar diabetes. El método comprende administrar a un sujeto que lo necesite dapansutrilo, o un solvato del mismo farmacéuticamente aceptable, en una cantidad eficaz. La administración oral es una vía de administración preferida.
MX2022011651A 2020-03-25 2021-03-22 Composicion farmaceutica para tratamiento de diabetes. MX2022011651A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US202062994486P 2020-03-25 2020-03-25
PCT/US2021/023497 WO2021194975A1 (en) 2020-03-25 2021-03-22 Method for treating diabetes

Publications (1)

Publication Number Publication Date
MX2022011651A true MX2022011651A (es) 2022-10-13

Family

ID=77890597

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2022011651A MX2022011651A (es) 2020-03-25 2021-03-22 Composicion farmaceutica para tratamiento de diabetes.

Country Status (7)

Country Link
US (1) US20230028615A1 (es)
EP (1) EP4132505A4 (es)
JP (1) JP2023518829A (es)
CN (1) CN115279363A (es)
AU (1) AU2021244313A1 (es)
MX (1) MX2022011651A (es)
WO (1) WO2021194975A1 (es)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN115089572A (zh) * 2022-07-18 2022-09-23 南通大学 一种化合物olt1177在制备治疗2型糖尿病药物制剂中的应用

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2018129347A1 (en) * 2017-01-06 2018-07-12 Olatec Therapeutics Llc Methods for treating cardiovascular diseases
WO2018204764A1 (en) * 2017-05-05 2018-11-08 Camp4 Therapeutics Corporation Identification and targeted modulation of gene signaling networks
ES2949404T3 (es) * 2017-07-24 2023-09-28 Novartis Ag Compuestos y composiciones para el tratamiento de afecciones asociadas a la actividad de NLRP

Also Published As

Publication number Publication date
EP4132505A4 (en) 2024-04-24
JP2023518829A (ja) 2023-05-08
WO2021194975A1 (en) 2021-09-30
EP4132505A1 (en) 2023-02-15
AU2021244313A1 (en) 2022-11-17
CN115279363A (zh) 2022-11-01
US20230028615A1 (en) 2023-01-26

Similar Documents

Publication Publication Date Title
MX2022006865A (es) Tetrahidrofuranos sustituidos como moduladores de canales de sodio.
NI201100147A (es) Métodos para tratar infartos agudos de miocardio y trastornos relacionados.
MX2021009199A (es) Conjugado de farmaco de dos ligandos y uso del mismo.
WO2021168483A3 (en) Treatment of human coronavirus infections using alpha-glucosidase glycoprotein processing inhibitors
MX2022015629A (es) Uso de vibegron para tratar vejiga sobreactiva.
PH12021550713A1 (en) Medicament for the treatment of chronic cough
AR119159A1 (es) Tratamientos de angioedema
MX2021009539A (es) Derivado del profarmaco 6-oxo-1,6-dihidropiridazina, metodo de preparacion del mismo y aplicacion del mismo en medicina.
MX2022000430A (es) Administracion de agonista de sting e inhibidores de puntos de control.
MX2022000143A (es) Metodos novedosos.
PH12019500618A1 (en) Pharmaceutical composition and method for treatment of non-alcoholic fatty liver disease
AU2020278236A8 (en) Methods of treating Sjögren's Syndrome using a Bruton's tyrosine kinase inhibitor
MX2022007911A (es) Procedimiento de tratamiento de una infeccion virica usando un agonista de tlr7.
MX2022011101A (es) Formulaciones de anticuerpos anti protofibrillas beta amiloide de alta concentracion y metodos de uso de las mismas.
MX2022011651A (es) Composicion farmaceutica para tratamiento de diabetes.
MX2021007330A (es) Composiciones y métodos terapéuticos para tratar cáncer usando ácido 6, 8-bis-benciltio-octanoico y un inhibidor de autofagia.
MX2022003845A (es) Tratamientos cognitivos medicinales.
MX2022012001A (es) Tratamiento preventivo de la migra?a.
MX2021015561A (es) Composiciones farmaceuticas que contienen dapansutrilo.
MX2022005596A (es) Regimen de dosificacion para agentes anti-dll3.
MX2022010407A (es) Forma de dosis oral de rápida dispersión de rimegepant.
MX2022009898A (es) Compuesto de dihidronaftiridinona y metodo de preparacion del mismo y uso medico del mismo.
MX2021015338A (es) Composicion que comprende pridopidina y un analogo de la misma para el tratamiento de la enfermedad de huntington y sintomas de la misma.
EA202193211A1 (ru) Лечение синуклеопатий
MX2022006414A (es) Vacuna triple contra avibacterium paragallinarum y el virus de la encefalomielitis aviar y el virus de la viruela aviar.